Aseptuva is developing far-UVC light disinfection technology at the catheter entry point to prevent hospital-acquired infections. The Swiss-British medtech raised CHF 2.4 million in seed funding last year from healthcare entrepreneurs and investors, which enabled it to reach preclinical validation.
- Announced on
- Round
- Seed
- Amount
- CHF 2.4 M
- Location
- Bern
- Sector
- Health & medtech
Investors
- Simon Michel
- Roger Nitsch
- Armin Diethelm
- Auxinam
- weInvest
- Valuemaker
- Fortyone
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic